View in EDS HTML Full Text PDF Full Text

An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD‐(L)1 Inhibitor.

Saved in:
Bibliographic Details
Title: An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD‐(L)1 Inhibitor.
Authors: Shi, Xun1 (AUTHOR), Lin, Chen1 (AUTHOR), Lou, Lishu1 (AUTHOR), He, Qiong1 (AUTHOR), Lou, Guangyuan1 (AUTHOR), Hong, Wei1 (AUTHOR), Shao, Lan1 (AUTHOR), Zhao, Jun1 (AUTHOR), Gu, Cuiping1 (AUTHOR), Yu, Xinmin1 (AUTHOR) yuxm@zjcc.org.cn, Jin, Ying1 (AUTHOR) jinying@zjcc.org.cn
Source: Cancer Medicine. Sep2025, Vol. 14 Issue 17, p1-9. 9p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20457634
DOI:10.1002/cam4.71191